There’s little doubt that Daiichi Sankyo has carved out a stronghold in the market for antibody-drug conjugates. Buoyed by its roster of ADCs, the company’s first-quarter revenue rose 21% over the ...

Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...

The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...

Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...

What if a cancer drug works, but not the way scientists thought it would? A recent study found evidence of just that in laboratory models of glioblastoma, involving the research compound QC6352 and a ...

Pharma has more drugs to test. But the system built to test them is under strain. The number of drugs in phase 2 and 3 has climbed about 9% year over year, according to a new analysis by Bain & ...

Right now is “singularly, the most exciting moment” in Daiichi Sankyo’s 100-year history, said Ken Keller, CEO and president of the company’s U.S. business and head of its global oncology unit. Riding ...

As patent protection for the cancer juggernaut Keytruda approaches a critical juncture, Merck & Co. won’t give up market share without a fight. The company revealed this week that a subcutaneous ...

CEOs can make or break a company. And new leaders at three of pharma’s largest drugmakers are taking over with little room for error. All three leaders took the ...

The FDA green-lit four drugs last year without any U.S. trial participants, according to CDER’s drug trials snapshot report, which summarizes the various demographics of clinical trials for approved ...

The fundamentals of leadership haven’t changed much in the more than three decades Dr. Mikael Dolsten has been a prominent figure in the pharma industry, most recently as chief scientific officer and ...